亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Multicenter Phase II Trial of Lenvatinib plus Hepatic Intra-Arterial Infusion Chemotherapy with Cisplatin for Advanced Hepatocellular Carcinoma: LEOPARD

伦瓦提尼 医学 顺铂 肝细胞癌 化疗 肿瘤科 内科学 索拉非尼
作者
Masafumi Ikeda,Tatsuya Yamashita,Sadahisa Ogasawara,Masatoshi Kudo,Yoshitaka Inaba,Manabu Morimoto,Kaoru Tsuchiya,Satoshi Shimizu,Yasushi Kojima,Atsushi Hiraoka,Kazuhiro Nouso,Hiroshi Aikata,Kazushi Numata,Tosiya Sato,Takuji Okusaka,Junji Furuse
出处
期刊:Liver cancer [Karger Publishers]
卷期号:13 (2): 193-202 被引量:18
标识
DOI:10.1159/000531820
摘要

<b><i>Introduction:</i></b> Hepatic arterial infusion chemotherapy (HAIC) with cisplatin and lenvatinib exhibits strong antitumor effects against advanced hepatocellular carcinoma (HCC). Higher antitumor activity is expected for the combination treatment. The aim of this trial was to evaluate the efficacy and safety of lenvatinib in combination with HAIC using cisplatin in patients with advanced HCC. <b><i>Methods:</i></b> In this multicenter, open-labeled, single-arm, phase II trial, patients with advanced HCC categorized as Child-Pugh class A with no prior history of systemic therapy were enrolled. Patients received lenvatinib plus HAIC with cisplatin (lenvatinib: 12 mg once daily for patients ≥60 kg, 8 mg once daily for patients &lt;60 kg; HAIC with cisplatin: 65 mg/m<sup>2</sup>, day 1, every 4–6 weeks, maximum of six cycles). The primary endpoint was the objective response rate (ORR) assessed using modified RECIST by the Independent Review Committee. The secondary endpoints were the ORR assessed using RECIST v1.1, progression-free survival, overall survival, and frequency of adverse events associated with the treatment. <b><i>Results:</i></b> A total of 36 patients were enrolled between September 2018 and March 2020. In the 34 evaluable patients, the ORR assessed by the Independent Review Committee using modified RECIST and RECIST v1.1 were 64.7% (95% confidence interval [CI]: 46.5–80.3%) and 45.7% (95% CI: 28.8–63.4%), respectively. The median progression-free survival and overall survival were 6.3 months (95% CI: 5.1–7.9 months) and 17.2 months (95% CI: 10.9 – not available, months), respectively. The main grade 3–4 adverse events were increased aspartate aminotransferase (34%), leukopenia (22%), increased alanine aminotransferase (19%), and hypertension (11%). <b><i>Conclusion:</i></b> Lenvatinib plus HAIC with cisplatin yielded a favorable ORR and overall survival and was well tolerated in patients with advanced HCC. Further evaluation of this regimen in a phase III trial is warranted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
背后梦安发布了新的文献求助30
刚刚
3秒前
善学以致用应助lf采纳,获得10
31秒前
39秒前
41秒前
lf发布了新的文献求助10
46秒前
47秒前
量子星尘发布了新的文献求助10
1分钟前
1分钟前
1分钟前
linkman完成签到,获得积分10
1分钟前
linkman发布了新的文献求助10
1分钟前
1分钟前
旅途规律完成签到,获得积分10
1分钟前
1分钟前
2分钟前
CodeCraft应助科研通管家采纳,获得10
2分钟前
充电宝应助科研通管家采纳,获得10
2分钟前
2分钟前
苹果果汁发布了新的文献求助30
2分钟前
charih完成签到 ,获得积分10
2分钟前
2分钟前
苹果果汁完成签到,获得积分10
2分钟前
兴尽晚回舟完成签到 ,获得积分10
2分钟前
CipherSage应助背后梦安采纳,获得30
2分钟前
量子星尘发布了新的文献求助10
2分钟前
2分钟前
3分钟前
3分钟前
3分钟前
3分钟前
3分钟前
3分钟前
3分钟前
mmm完成签到 ,获得积分10
3分钟前
4分钟前
Ava应助科研通管家采纳,获得10
4分钟前
4分钟前
4分钟前
李治稳发布了新的文献求助10
4分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976649
求助须知:如何正确求助?哪些是违规求助? 3520749
关于积分的说明 11204693
捐赠科研通 3257497
什么是DOI,文献DOI怎么找? 1798716
邀请新用户注册赠送积分活动 877897
科研通“疑难数据库(出版商)”最低求助积分说明 806629